IBIO · XBRL financial data
iBio financial statements, every fiscal year
The same tables from 10 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (IBIO's year ends in late June)
| In thousands of dollars | Jun 30, 2021 | Oct 7, 2022 | †Jun 30, 2023 | Jun 30, 2024 | Jun 30, 2025 | Jun 30, 2026 |
|---|---|---|---|---|---|---|
| Revenue | 2,371 | — | 0 | — | — | — |
| Revenue from contracts with customers | — | — | 0 | 225 | 400 | 100 |
| Cost of goods and services sold | 1,462 | — | — | — | — | — |
| Gross profit | 909 | — | — | — | — | — |
| Research and development | 9,989 | — | 10,327 | 5,185 | 8,312 | 19,643 |
| General and administrative | 22,031 | — | 19,016 | 11,674 | 10,690 | 10,595 |
| Total operating expenses | 32,020 | — | 29,343 | 16,859 | 19,002 | 35,241 |
| Operating income (loss) | (31,111) | — | (29,343) | (16,634) | (18,602) | (35,141) |
| Interest income | 140 | — | 213 | 363 | 437 | 2,150 |
| Interest expense | 2,454 | — | 83 | 172 | 212 | 53 |
| Income tax expense (benefit) | 0 | — | 0 | 0 | 0 | 0 |
| Net income (loss) | (23,207) | — | (65,010) | (24,907) | (18,377) | (33,044) |
| Earnings per share, basic‡ USD per share | (60.00) | — | (106.20) | (6.50) | (1.75) | (0.32) |
| Earnings per share, diluted‡ USD per share | (60.00) | — | (106.20) | (6.50) | (1.75) | (0.32) |
| Weighted average shares, basic‡ thousands of shares | 391 | — | 612 | 3,831 | 10,499 | 104,060 |
| Weighted average shares, diluted‡ thousands of shares | 391 | — | 612 | 3,831 | 10,499 | 104,060 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (October 2022); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (November 2023); filings made before it reported them unadjusted.
- † Share count changed about 3x in the period ending 2023-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (IBIO's year ends in late June)
| In thousands of dollars | Jun 30, 2021 | Oct 7, 2022 | †Jun 30, 2023 | Jun 30, 2024 | Jun 30, 2025 | Jun 30, 2026 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 77,404 | — | 4,301 | 14,210 | 8,582 | 56,395 |
| Marketable securities | 19,570 | — | — | 0 | 0 | 31,600 |
| Accounts receivable | 426 | — | 0 | 0 | — | — |
| Inventory | 27 | — | 0 | 0 | — | — |
| Prepaid and other current assets | 2,070 | — | 664 | 749 | 1,034 | 3,078 |
| Total current assets | 104,597 | — | 26,259 | 15,672 | 9,721 | 92,221 |
| Property and equipment, net | 8,628 | — | 4,219 | 3,632 | 3,163 | 3,086 |
| Right-of-use asset | 0 | — | 2,722 | 2,401 | 2,051 | 1,667 |
| Total assets | 146,968 | — | 41,207 | 28,734 | 23,185 | 99,110 |
| Accounts payable | 2,254 | — | 1,849 | 358 | 2,188 | 4,423 |
| Accrued liabilities | 3,001 | — | 4,034 | 2,028 | 1,345 | 5,626 |
| Total current liabilities | 6,645 | — | 21,582 | 3,840 | 6,106 | 11,745 |
| Lease liability, non-current | 0 | — | 3,125 | 2,688 | 2,199 | 1,652 |
| Total liabilities | 38,400 | — | 25,826 | 7,410 | 8,305 | 13,397 |
| Accumulated deficit | (173,627) | — | (288,940) | (313,847) | (332,224) | (365,268) |
| Total stockholders' equity | 108,585 | — | 15,381 | 21,324 | 14,880 | 85,713 |
| Total liabilities and equity | 146,968 | — | 41,207 | 28,734 | 23,185 | 99,110 |
| Common shares outstanding (cover page)‡ thousands of shares | 436 | 450 | 1,379 | 8,638 | 19,655 | 64,307 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (October 2022); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (November 2023); filings made before it reported them unadjusted.
- † Share count changed about 3x in the period ending 2023-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (IBIO's year ends in late June)
| In thousands of dollars | Jun 30, 2021 | Oct 7, 2022 | †Jun 30, 2023 | Jun 30, 2024 | Jun 30, 2025 | Jun 30, 2026 |
|---|---|---|---|---|---|---|
| Net income (loss) | (23,207) | — | (65,010) | (24,907) | (18,377) | (33,044) |
| Stock-based compensation | 1,586 | — | 4,391 | 2,038 | 1,530 | 1,373 |
| Net cash from operating activities | (30,064) | — | (30,436) | (18,554) | (15,304) | (23,218) |
| Purchases of property and equipment | 4,920 | — | 5,738 | 210 | 16 | 578 |
| Net cash from investing activities | (26,478) | — | 7,009 | 906 | 742 | (31,999) |
| Proceeds from issuing common stock | — | — | 11,487 | 25,523 | 3,541 | 3,529 |
| Net cash from financing activities | 78,835 | — | 2,301 | 24,494 | 8,929 | 103,048 |
| Net change in cash | 22,292 | — | (21,093) | 6,846 | (5,633) | 47,831 |
- † Share count changed about 3x in the period ending 2023-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| iBio | 56,395 | 0* | (6,228)* | 64.3M | 14.1 quarters | 10-KJun 30, 2026 |
| Sutro Biopharma | 54,335 | 9,839 | (38,290)* | 16.6M | 4.3 quarters | 10-QJun 30, 2026 |
| PDS Biotechnology | 5,596 | not reported | (2,793)* | 56.0M | 2.0 quarters | 10-QJun 30, 2026 |
| Avalo Therapeutics | 85,382 | not reported | (19,988)* | 53.6M | 20.0 quarters | 10-QJun 30, 2026 |
| Medicinova | 25,416 | 458 | (1,920)* | 49.2M | 13.2 quarters | 10-QJun 30, 2026 |
| Cue Biopharma | 17,392 | 7,877 | (29,004)* | 7.3M | 0.6 quarters | 10-QJun 30, 2026 |
| Lifevantage | 14,920 | 42,377* | 4,767* | 12.5M | — | 10-KJun 30, 2026 |
| Veru | 23,880 | not reported | (5,467)* | 17.1M | 4.4 quarters | 10-QJun 30, 2026 |
| Whitehawk Therapeutics | 85,234 | 0 | (14,529)* | 57.0M | 13.1 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.